A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Inclusion Criteria Volunteers must have: Negative ELISA for HIV within 8 weeks prior to immunization. CD4 count greater than or equal to 400 cells/mm3. Normal history and physical examination. [Refer to Laboratory values for additional requirements.] Exclusion Criteria Co-existing Condition: Volunteers with the following conditions or symptoms are excluded: Medical or psychiatric conditions or occupational responsibilities which preclude subject compliance with the protocol. Recent suicidal ideation or psychosis. Active syphilis. NOTE: If the serology is documented to be a false positive or due to a remote (greater than 6 months) treated infection, the volunteer is eligible. Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest x-ray showing no evidence of TB and not requiring INH therapy are eligible. Positive for hepatitis B surface antigen. Volunteers with the following prior conditions are excluded: History of immunodeficiency, chronic illness, or autoimmune disease. History of cancer unless there has been surgical excision followed by a sufficient observation period to give a reasonable assurance of cure. History of suicide attempts, recent suicidal ideation, or past or present psychosis. History of anaphylaxis or other serious adverse reactions to vaccines. History of serious allergic reaction to any substance requiring hospitalization or emergency medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension). History of reaction to thimerosal. Prior Medication: Excluded: Live attenuated vaccine within 60 days of study. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary, but should be given at least 2 weeks away from HIV immunizations. Experimental agents within 30 days prior to study. HIV-1 vaccines or placebo as part of a previous HIV vaccine trial. Prior Treatment: Excluded: Blood products or immunoglobulin in the past 6 months. Experimental agents within 30 days prior to study. Risk Behavior: Excluded: Volunteers with an identifiable higher- or intermediate-risk sexual behavior for HIV infection (i.e., AVEG Risk Groups C or D ). History of intravenous drug use within 12 months prior to enrollment.